Ligand Pharmaceuticals Incorporated (LGND) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Margins ⢠High Liquidity ⢠Premium Pricing LGND shows strong profitability, exceptional liquidity, and low leverage, but its premium valuation leaves limited margin of safety.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Strong rebound ⢠Near resistance Support Level: $223 to $226 Resistance Level: $232 to $233 LGND's last month trend is constructive, with higher highs/lows and a strong rebound, but it is now nearing $232â$233 resistance and may need a catalyst to extend further.
Sentiment & News
Key News Insights: ⢠Strategic hiring ⢠FDA approval ⢠Insider selling Ligand's recent news is broadly constructive, with strategic hiring, partner milestone/approval-driven royalty upside, and supportive analyst sentiment offset by some insider and institutional selling.
AI Summary
LGND has evolved into a high-quality cash compounder with real new royalty catalysts, but after a strong run the investment case now hinges on continued partner-driven execution and fresh deal deployment to justify its premium valuation.
Description
Ligand Pharmaceuticals develops or acquires technologies that support pharmaceutical companies in discovering and developing medicines, commercializing a portfolio that spans oncology, infectious disease, endocrine and bone health, vaccines, and other specialty treatments. The company also partners on and licenses programs in clinical development targeting cancer, neurological, metabolic, cardiovascular, and other conditions, and it manufactures Captisol excipient materials. Founded in 1987, Ligand is headquartered in Emeryville, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | LGND | Ligand Pharmaceuticals Incorporated | Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50. | Active | +0.0% |